comparemela.com

Latest Breaking News On - Orphan drug status - Page 1 : comparemela.com

Rx Rundown: AbbVie, Eli Lilly, Roche and more

Check out this week’s medical marketing news, dealmaking and industry chatter.

Roche elecsysRoche genentechAstrazeneca imfinziAsher bioEli lillyHealth economics outcomes research solutionsCenters for diseaseIlant healthPractices groupDrug administrationOmnicom groupMarinus pharmaceuticalsRinger sciencesTakeda pharmaceuticalsKumquat biosciencesAdaptimmune therapeutics

KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update

- Sebetralstat Phase 3 KONFIDENT Clinical Trial Achieves Targeted Number of Attacks to Complete Trial - - Data Readout on Track for Early 2024; NDA Filing Expected H1 2024 - .

Andrew crockettInternational conferenceEuropean unionExchange commissionAsia pacific association of allergyKalvista pharmaceuticals incDrug administrationKalvista pharmaceuticalsChief executive officerFiscal quarterRecent business highlightsNew drug applicationOrphan drug statusScientific meetingAmerican collegeCantor global healthcare conference

UK S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI s Multikine as Potential New Standard of Care for Head & Neck Cancer

VIENNA, Va. (BUSINESS WIRE) $CVM #Multikine CEL-SCI Corporation (NYSE American: CVM) today announced that the British National Institute for Health and Care Excellence (NICE) has selected Multikine (Leukocyte Interleukin, Injection) to be evaluated as the potential new standard of care for squamous cell carcinom.

United kingdomUnited statesMehmet senGeert kerstenExchange commissionDepartment of healthHealth technology briefingUnited kingdom national institute for healthEngland national health serviceBritish national institute for healthSecurities exchangeCare researchCancer research united kingdomJames institute of oncologyBritish national instituteCare excellence

CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock

CEL-SCI Corporation , a Phase 3 cancer immunotherapy company, today announced the closing of its previously announced public offering of 2,490,000 shares of its common stock to a single investor at.

United statesNew yorkExchange commissionSecurities exchangeOrphan drug statusSecurities actSecurities exchange act

CEL-SCI Announces Pricing of $5 Million Offering of Common Stock

CEL-SCI Corporation , a Phase 3 cancer immunotherapy company, today announced the pricing of an offering of 2,490,000 shares of its common stock to a single investor at an offering price of $2.00.

United statesNew yorkExchange commissionSecurities exchangeOrphan drug statusSecurities actSecurities exchange act

vimarsana © 2020. All Rights Reserved.